Latest Insider Transactions at Ab Cellera Biologics Inc. (ABCL)
This section provides a real-time view of insider transactions for Ab Cellera Biologics Inc. (ABCL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of AbCellera Biologics Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of AbCellera Biologics Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 31
2021
|
John Hamer Director |
SELL
Open market or private sale
|
Direct |
162,649
-37.93%
|
$2,602,384
$16.95 P/Share
|
|
Aug 16
2021
|
John S. Montalbano Director |
BUY
Open market or private purchase
|
Direct |
6,000
+18.75%
|
$102,000
$17.23 P/Share
|
|
Jun 22
2021
|
Michael R Hayden Director |
SELL
Open market or private sale
|
Indirect |
100,000
-9.06%
|
$2,500,000
$25.5 P/Share
|
|
Jun 18
2021
|
Dcvc Bio, L.P. > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
73,892
+50.0%
|
-
|
|
Jun 18
2021
|
Dcvc Bio, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
5,000,000
-17.18%
|
-
|
|
Jun 18
2021
|
John Hamer Director |
BUY
Other acquisition or disposition
|
Indirect |
73,892
+50.0%
|
-
|
|
Jun 18
2021
|
John Hamer Director |
SELL
Other acquisition or disposition
|
Indirect |
5,000,000
-17.18%
|
-
|
|
Jun 15
2021
|
Veronique Lecault Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
333,333
+19.93%
|
$0
$0.19 P/Share
|
|
Jun 09
2021
|
Andrew Booth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,200,000
-100.0%
|
$30,000,000
$25.5 P/Share
|
|
Jun 09
2021
|
Ester Falconer Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
1,000,000
-100.0%
|
$25,000,000
$25.5 P/Share
|
|
Jun 09
2021
|
Tryn Stimart Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,000,000
-99.98%
|
$25,000,000
$25.5 P/Share
|
|
Jun 09
2021
|
Veronique Lecault Chief Operating Officer |
SELL
Open market or private sale
|
Indirect |
1,000,000
-78.52%
|
$25,000,000
$25.5 P/Share
|
|
Jun 09
2021
|
Carl L. G. Hansen Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
6,000,000
-36.19%
|
$144,000,000
$24.77 P/Share
|
|
Jun 09
2021
|
Thermopylae Holdings Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
5,598,420
-9.15%
|
$134,362,080
$24.03 P/Share
|
|
Jun 07
2021
|
Andrew Booth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,200,000
+41.67%
|
$0
$0.26 P/Share
|
|
Jun 07
2021
|
Tryn Stimart Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000,000
+34.99%
|
$1,000,000
$1.31 P/Share
|
|
Mar 19
2021
|
Ester Falconer Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000,000
+50.0%
|
$0
$0.03 P/Share
|
|
Dec 15
2020
|
Tryn Stimart Chief Legal Officer |
BUY
Open market or private purchase
|
Indirect |
250
+50.0%
|
$5,000
$20.0 P/Share
|
|
Dec 15
2020
|
Tryn Stimart Chief Legal Officer |
BUY
Open market or private purchase
|
Direct |
250
+50.0%
|
$5,000
$20.0 P/Share
|
|
Dec 15
2020
|
Michael R Hayden Director |
BUY
Open market or private purchase
|
Indirect |
73,665
+38.39%
|
$1,473,300
$20.0 P/Share
|
|
Dec 15
2020
|
Michael R Hayden Director |
BUY
Conversion of derivative security
|
Indirect |
117,647
+9.64%
|
-
|
|
Dec 15
2020
|
Veronique Lecault Chief Operating Officer |
BUY
Open market or private purchase
|
Indirect |
17,000
+21.63%
|
$340,000
$20.0 P/Share
|
|
Dec 15
2020
|
Veronique Lecault Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
6,000
+0.59%
|
$120,000
$20.0 P/Share
|
|
Dec 15
2020
|
John S. Montalbano Director |
BUY
Open market or private purchase
|
Indirect |
5,000
+50.0%
|
$100,000
$20.0 P/Share
|
|
Dec 15
2020
|
John S. Montalbano Director |
BUY
Open market or private purchase
|
Direct |
20,000
+50.0%
|
$400,000
$20.0 P/Share
|
|
Dec 15
2020
|
Peter Thiel Director |
BUY
Conversion of derivative security
|
Indirect |
10,468,907
+45.77%
|
-
|
|
Dec 15
2020
|
Peter Thiel Director |
BUY
Open market or private purchase
|
Indirect |
3,000,000
+22.76%
|
$60,000,000
$20.0 P/Share
|
|
Dec 15
2020
|
Dcvc Bio, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
29,105,761
+25.05%
|
-
|
|
Dec 15
2020
|
John Hamer Director |
BUY
Conversion of derivative security
|
Indirect |
29,105,761
+25.05%
|
-
|
|
Nov 06
2020
|
Michael R Hayden Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
270,000
+21.5%
|
$0
$0.33 P/Share
|